Vtd combination therapy with bortezomib–thalidomide–dexamethasone is highly effective in advanced and refractory multiple myeloma
April 25th, 2008 by 
admin VTD compounding therapy with bortezomib–thalidomide–dexamethasone is highly trenchant in modern and disobedient binary myeloma
Leukemia front online publication, Apr 24, 2008. doi:10.1038/leu.2008.99
Authors: M Pineda-Roman, M Zangari, F camper Rhee, E Anaissie, J Szymonifka, A Hoering, N Petty, J Crowley, J Shaughnessy, J Epstein
& B Barlogie (Source: Leukemia)
Posted in Cancer | 